-
The views expressed herein do not constitute research, investment advice or trade recommendations, do not necessarily represent the views of all AB portfolio-management teams and are subject to change over time.
After a strong year for China stocks, could improving fundamentals and accelerating earnings growth deliver more for investors?
In a year that surprised skeptics, China equities delivered strong performance in 2025, buoyed by improving corporate fundamentals, strengthening earnings and policy reforms. China enters 2026 on solid ground for further gains, though it will take a selective approach to tap into the next stage of recovery.
Offshore China equities and “A shares”—shares of mainland Chinese firms that trade on two major exchanges—have delivered two consecutive years of double-digit gains following an extended period of underperformance. The broad-based recovery has incorporated diverse corners of the economy. Over the coming year, we believe the conversation around China won’t be whether the world’s second-largest economy is investible, but rather how best to allocate to China.
Over the long term, equity market returns are driven by earnings. That helps explain why Chinese stocks struggled for much of the past decade as earnings-per-share (EPS) growth stagnated. Some of this weakness was cyclical, but there were also structural elements at play. China has been going through a familiar East Asian growth pattern—export-led expansion, rising wealth, a property boom and then a correction. Korea and Japan lived through similar chapters. These transitions are painful, but they are not unique or permanent.
China equities have also been hindered by poor price discipline, deflation and overcapacity—not to mention high issuance levels that diluted EPS growth. Fortunately for investors, dividends and buybacks have become more common, and net issuance has turned negative. It’s early, but directionally, this matters. And in a policy pivot, China has put the brakes on “involution”—the draconian price cuts previously employed to stimulate consumer spending and economic growth. Anti-involution is part of China’s 15th Five-Year Plan and an underappreciated market driver, in our view.
In aggregate, these shifts have had a positive effect on margins. We think return on equity may have reached an inflection point, with consensus EPS growth estimates for the broad-market CSI 300 Index outpacing the S&P 500 and MSCI EAFE (Display). These upbeat expectations are anchored in genuine earnings recovery rather than market sentiment—a marked change from previous years.
Historical and current analyses do not guarantee future results.
Earnings estimates are in local-currency terms. China A represented by CSI 300 Index; China Offshore represented by MSCI China.
As of December 31, 2025
Source: Goldman Sachs and AllianceBernstein (AB)
Meanwhile, the level of untapped savings is supportive, too, in China’s retail-heavy stock market. Chinese households have accumulated significant savings since 2021, due primarily to reduced property purchases. With bank deposit rates low and bond yields compressed, equities stand out as perhaps the most viable risk asset. Chinese consumers have taken note, driving the MSCI China A Onshore Index up 26.1% in 2025.
To be sure, the rally is still early and its progression won’t likely be linear. The latest macro data point to an economic recovery in China that will be uneven at best. Still, we see early signs of stabilization in recovering exports, industrial upgrades and travel-related areas such as hotels and Macau gaming.
Despite the rebound in China equities, many global investors have scant allocations to China. With the Fed poised to cut rates and the US dollar under pressure, global investors are seeking alternatives to dollar-denominated risk assets. Europe and Japan have absorbed some of that reallocation, but China remains under-allocated (Display). If more global investors begin shifting more assets toward China, it could be a long-term catalyst for the stock market.
Historical analysis does not guarantee future results.
*Includes global emerging markets, Asia ex-Japan, global and global ex-US funds with total assets under management of $1.3 trillion.
Through November 30, 2025
Source: EPFR, Goldman Sachs and AB
Light allocations in China are reflected in valuations, with A shares particularly cheap even after last year’s rally. As of 2025 year-end, the CSI 300 Index of onshore Chinese stocks was trading at 13.9 times forward price to earnings. While that’s above its historical average, it’s below prior peaks and represents a sizeable discount to the S&P 500 and MSCI EAFE. This leaves plenty of room for multiple expansion as earnings visibility improves—particularly given the weak US dollar, which can support emerging-market assets (Display).
Historical analysis does not guarantee future results.
Right display is based on weekly relative returns between CSI 300 and S&P 500 in USD terms.
EM is represented by MSCI Emerging Markets Index; DM is represented by MSCI World Index.
Through December 31, 2025
Source: Bloomberg, MSCI and AB
Markets have largely adjusted to China’s new baseline, and are reacting to headlines with relative calm. Still, volatility remains part of investing in China given the ongoing policy shifts and global trade dynamics. Moreover, China remains a relatively inefficient market. But this inefficiency, coupled with rapid structural change, is creating opportunities in companies across diverse industries. Even when macroeconomic narratives dominate market sentiment, active managers can find fertile ground to generate alpha by tapping into mispriced companies with solid earnings potential at attractive valuations.
After more than a decade of stagnation, China’s equity market appears to be on the upswing. China is a deep, liquid and highly investable alternative for investors looking to expand upon existing global allocations. But market sentiment is likely to be uneven for the foreseeable future, making bottom-up stock selection critical to achieving success in this evolving market.
The views expressed herein do not constitute research, investment advice or trade recommendations, do not necessarily represent the views of all AB portfolio-management teams and are subject to change over time.
MSCI makes no express or implied warranties or representations, and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed or produced by MSCI.
Investment involves risk. The information contained here reflects the views of AllianceBernstein L.P. or its affiliates and sources it believes are reliable as of the date of this publication. AllianceBernstein L.P. makes no representations or warranties concerning the accuracy of any data. There is no guarantee that any projection, forecast or opinion in this material will be realized. Past performance does not guarantee future results. The views expressed here may change at any time after the date of this publication. This article is for informational purposes only and does not constitute investment advice. AllianceBernstein L.P. does not provide tax, legal or accounting advice. It does not take an investor's personal investment objectives or financial situation into account; investors should discuss their individual circumstances with appropriate professionals before making any decisions. This information should not be construed as sales or marketing material or an offer of solicitation for the purchase or sale of, any financial instrument, product or service sponsored by AllianceBernstein or its affiliates. This presentation is issued by AllianceBernstein Hong Kong Limited (聯博香港有限公司) and has not been reviewed by the Securities and Futures Commission.